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EDITORIAL
Standard and Method Independent Units for
Heparin Anticoagulant Activities
H.  C .  Hemker  and  S .  869u in
From the Department  of  Biochemist ry ,  Cardiovascular  Research Inst i tu te and Univers i ty  of  L imburg,
Maastr icht ,  The Nether lands
Summary
It is discussed why the current USP unit of heparin anticoagu-
lant activity necessarily will render inaccurately the anticoagulant
activities of low molecular weight heparins. It is shown that the
outcome is bound to vary with the method used for comparison of
the sample and the standard and with the nature of the standard
used. As an alternative we define a unit of heparin in terms of
anti-factor Xa- and antithrombin-activity that is independent of
the heparin standard and of the assay method, but that is based
upon a quantitative description of the catalytic effect of heparin
on AT III mediated thrombin- and factor Xa breakdown. Expres-
sion of the results of existing anti-factor Xa- and antithrombin
tests in terms of these units will allow to express heparin levels in
plasma in terms of concentrations of active anticoagulant mate-
rial. This approach makes it possible to separate heparin phar-
macodynamics from heparin pharmacokinetics. Introduction of
this unit does not require adaptation of current laboratory
practice but changes the way in which the results obtained are
expressed.
lntroduction
In the early 1920's, Howell (1) defined a unit of heparin as that
amount of heparin that causes such retardation of coagulation
that a millilitre of cat blood will half-clot when left during one
night in the refrigerator. The United States Pharmacopoeia (USP
unit), that also figures in many national pharmacopoeias. is
similarly defined as that amount of heparin that will cause 1 ml of
sheep plasma to half-clot when kept for t h at 37" C (see also 2 for
a discussion). The International Unit (I U.) is defined via the
lnternational Heparin Standard (I. H. S.) which itself is calibrated
via all the major assay methods.
The direct determination of heparin concentrations in plasma
from patients is impossible with the USP method. A large number
of other tests is available for this purpose: thrombin time,
activated partial thromboolastin time in a multitude of varieties
Abbreviations used: Nl III: antithrombin III; USP: United States
pharmacopoeia; IU: International unit; SIU: standard independent unit;
UFH: unfractionated heparin; LMWH: low molecular weight heparin;
HAM: high affinity material; ACLM: above critical chainlength material;
BCLM: below critical chainlength material; APTT: activated partial
thromboplastin time.
Correspondence to: Dr H. C. Hemker, Dept. of Biochemistry,
Cardiovascular Research Institute of Limburg, P O Box 676, 6200 MD
Maastricht, The Netherlands
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(APTT), and several tests based on the measurement of the decay
of added thrombin or factor Xa. In order to express the results of
these tests in terms of USP units, they need to be calibrated with a
standard preparation, the potency of which has been determined
in terms of USP procedure. An important problem in the
determination of the heparin concentration by comparison to a
standard remains, however, that the outcome will be dependent
upon the method used for comparison (see below).
The anticoagulant effect used for the definition of the USP unit
is far from being specific; any anticoagulant activity can be
expressed in these units. Therefore the USP unit can be used in a
meaningful way only as long as fairly similar preparations of
heparin are compared. It appears to be a poor tool even to
compare low molecular weight heparins to the unfractionated
heparin standard (3, 4). Indeed its replacement is being consi-
dered (5, 6). Replacement by what, however? In this paper we
propose a unit of heparin activity that is not dependent upon the
use of a special method and that also is not primarily defined as
the activity of a given standard preparation even though in
practice standard preparations will remain a necessary means to
compare the results in different laboratories.
Biochemical Backgrounds; Heparin
Heparins act on blood coagulation by binding to AT III and
enhancing its inhibitory action on thrombin, factor Xa and other
blood coagulation enzymes (7-10). Active heparins contain a
specific pentasaccharide sequence with which they bind to AT III
(see 11 for a review). Only about 30-40% (weight) of UFH
contains this sequence. This fraction we call High Affinity
Material (HAM). Within HAM we distinguish two classes
(Fig. 1): molecules longer than the critical chainlength of 17
monosaccharide units (Above Critical chain Length Material:
ACLM, with a Mw >5,400) and molecules below that chainlength
(BCLM). ACLM catalyses both factor Xa and thrombin inactiva-
tion but BCLM catalyses only factor Xa-inactivation As dis-
cussed in detail in ref. 12 (pp 2326 and references therein), the
cutoff point between ACLM and BCLM heparins can indeed be
localised with fair precision around 5,400 MW or 17 monosac-
charide units. Our own data also support this conclusion (n, M).
Different types of heparin may differ as to the HAM content as
well as to the partition of the HAM fraction between ACLM and
BCLM. In a series of 4 commercially available LMWH prepara-
tions the ACLM contents ranged from L0 to 30% and the BCLM
contents from 1 to 12%. The HAM content of LMWHs decreases
proportionally with the mean molecular weight (14). This seems a
logical consequence from the fact that LMWHs are obtained from
UFH by chemical or enzymatical splitting of the molecules in a
random fashion. A HAM molecule of around 9,000 MW will
consist of some 30 monosaccharide units. If such a molecule is
UFH
LMWH 1 0.153 0.030 0.065 0 022
LMWH2 0r89 0042 0090 0.027
PENTA 0 800 0.480 0 520
B: Dose doubling the APTT
UFH 0.62 0 059 0.192
LMWH 1 21 0.420 0 9
LMWH 2 2 . r  0 .470 10
PENTA 50 29 40 32.5
0.077 0.0074 0.025 0.025
Tabte 1 Comparison of the activities of different heparins
HAM HAM International
Units
aXa aIIa
S. I.  Units
pg/ml pM aXa aIIa
A: IC50 of the surface under the thrombin generation curve (intrinsic)
HAM molecules count, for the decay of thrombin only the ACLM
fraction.
The Confusion Inherent to the Old Units
Inhibition of blood clotting, as used in the determination of the
USP unit or the APTT can be obtained both by ACLM and by
BCLM, but the activity per unit weight of ACLM is much higher
than that of BCLM (13, 14). In Thble 1 it is seen that
concentrations of different heparins with comparable biological
ACLM and BCLM for the test outcome is therefore completely
dependent upon the test used.
Obviously only a standard with an identical ratio of
ACLM:BCLM as the sample to be tested will not be influenced
by the type of test used. This is the rationale behind the usefulness
of the i LMWH standard (4). This standard is a mixture of
ACLM and BCLM, the composition of which approaches the
composition of other LMWHs better than the UFH standard
does. But the units of a LMWH standard, nor of any other
LMWH can be compared to units of UFH' in which hardly any
BCLM is present.
A second complication is that the UFH standard, like all other
UFHs but unlike LMWHs, has a low anti-factor Xa activity in the
absence of Ca2+, i. e. in all current anti-Xa tests. Any LMWH in
these tests is measured against a "handicapped" standard and
hence is overestimated (19).
The following may scrve as an illustration We took 0'01 USP unit of
standard heparin and determined the amount of a I-MWH that in a
commercial, amidolytic anti-factor Xa test showed the same activity, so
that by definition it contained also 0.01 USP unit of anti-factor Xa
activity. This, in fact is the way in which the manufacturers arrive at the
amount of activity declared on the label. For technical rea^sons current
anti-factor Xa tests are carried out in the absence of Ca'* ions' We
estimated the anti-factor Xa activity of the standard heparin preparatron
and of the "equipotent" LMWH solution in the presence of a physiologi- 
- .
cal concentration of Ca2* ions and found the UFH preparation to be 137 \- ir
times as potent as the LMWH. In thc body heparin acts in the presence of
Ca2* ions. so the labcl of thc LMWH must be judged to overestimate the
contents by 1.86 times (see also 19).
So the label on the LMWH bottle overestimates the potency of its
contents nearly two timcs. Similar results were obtained with other
LMWHs, including the international standard for LMWH'
The confusion stems from two sources' In the first place the
test conditions may differ considerably from the conditions in the
body. In the second place we try to assign a unique potency to a
drug that, at the simplest, is a mixture of two distinct active
substances: ACLM and BCLM, the proportion of which is not the
same in the standard and in the preparation to be tested.
A Proposal for Standard- and Method Independent Units
In the presence of HAM the decay constant of factor Xa
increases proportionally to the heparin-concentration and to the
concentration of AT III in the plasma. This property we can use
to define a standard- and method independent unit (SlU) of
HAM activity (16,l7).
Definition. One standard independent unit of anti-factor Xa
activity (SIU-Xa), of heparin is that amount of heparin'that, in
0 373 1.198
0 357 r.1.64
0.434 r.047
- 0.495
0 r92 r.97 6.36
0.3 3.29 l0 72
0.3 3.20 7 '72
- 165
Thrombin generation curves were determined as in ref. 13 The APTT was
carried out manually by mixing 0.1mI plasma sample, 0'1ml Actin FS
(Baxter Diagnostics) , after 2 min mixing at 37" C, 0.7 m1 CaCl2 (25 mM)
was added and the clotting time read by tilting. The dose was sought that
in 9 out of 10 experiments prolonged the blank of 35 s to between 68 and
'72 
s. Molar concentrations of HAM were obtained directly via AT III
fluorescence titration
split in two random parts, than there is a 5 in 30 chance that the
pintasaccharide sequence will be split that is responsible for
AT III binding and two LAM molecules will result.
Biochemical Backgrounds: Kinetics of Clott ing Factor Decay
The inactivation of thrombin, factor Xa and other activated
clotting enzymes by AT III in plasma is a bimolecular reaction
(E + A !. I*; that according to standard chemical kinetics has a
ieaction velocity of u, -- k ' A, ' Er. The concentration of AI III in
plasma is about 2.5 p,M.In every well designed decay experiment
iare is taken to keep the initial enzyme concentration below a
certain proportion (e. g. 30 times less) of the AT III concentra-
tion. Therefore A, can be considered constant and the enzyme
decay can be described by pseudo-first order kinetics. The decay
velocity of the enzyme is therefore expressed by vr : k ' Ao ' E,, ot v
:ka"" ' E,, wherc ka." : k ' As.In this situation the time-course of
,E is given bY E, : Eo e r<d" t; i' e' the enzyme decays
semilogarithmically as e.g. a radioactive element. The decay
constant is inversely proportional to the half-life time of the
enzyme'. kd". : 0.6931tr**. The dimension-of k6." therefore is
inverse time, usually it is expressed in min-t. Heparin catalyses
the above reaction. The mechanism of catalysis may be complex
(15), its effect is simple: it decreases the half-life time and
increases the decay constant k,1"". In plasma, at heparin concentra-
tions that may be encountered in actual prophylactic and
therapeutic practice, the increase of the decay constant is
proportional to the AT III concentration and to the concentration
of heparin: ka"": k ' A ' H' This proportionality' that was found
for all the different heparins that we tested (13, 14, 16-18), we
will use as a basis for the definition of a heparin unit. It is
important to notice that in this formula 11 stands for the
concentration of active heparin. For the decay of factor Xa only
* In the reaction equation E : enzyme (thrombin, factor Xa etc.),
A : AT III, 1 : inactive product. In thc kinetic equations the letters
stand for the concentrations of these reactants. The subscripts denote the
t ime, E{r  enzyme concenlrat ion at  zero t ime etc
+x Because at the half-life time half of the original material is left, and
the natural logarithm of /: equals -0.693.
725
6!
;
5 4 Molecular W€ight (kD)
Fig 1 Schematic representation of the molecular weight distribution
unfractionated and in low molecular weight heparin (see text)
BCLM-LMWH
/ A.LM-,FH
The units thus defined are not dependent upon a standard or
upon a specific methodology. This does not mean that in practice
one or more heparin standards would not be useful or even
necessary. The use, in the definition, of the words "in normal
plasma" implies that the reaction conditions should be as near as
possible to physiological Ca?+ concentration, temperature, qual-
ity of enzyme, presence of other proteins etc. Reproducible
results in different laboratories can only be obtained if the
methods are rather strictly defined. If the method is not com-
pletely defined then the use of a standard calibrated in the new
units can minimise errors due to experimental variationS. In
principle the deviations from physiological conditions do not
count then any more, and any anti-thrombin or anti-factor Xa
method that is now in use can be applied to determine heparin
contents in terms of the new units, when thus calibrated against
well defined standards of anti-factor Xa- and anti-thrombin
activity. The only caveat is that the standard and the heparin in
question should react in the same way to changes in the reaction
conditions. This is not the case e. g. when LMWHs are compared
to a UFH standard in mixtures without Ca'* ions (19, see also
above). From Thble'1 it is seen that heparin concentrations that
have similar effects on thrombin generation have comparable
activities when expressed in S.I. Units.
Specific Activities of Heparins,
their Use in Heparin Pharmacology
We can express the specific activity of a heparin in terms of the
SI units. To do this, we determine how much 1 pg of the heparin
under investigation will increase the decay constants of factor Xa
and of thrombin in a normal plasma with a known AT III content.
If the addition of 1 pg of the heparin to 1 ml of plasma increases
the decay constant from 0.490 min 1 (the normal value without
heparin) to 4.740 min-1 per pM of AIIII, than the specific
activity of that heparins is 4.250 SIU-Xa per pg of crude material.
In the crude material only the HAM is responsible for this
activity, it therefore is logical to express this activity per pg or per
nMole of HAM (Table 2).
In a completely analogous way we can determine the specific
anti-thrombin activily of a heparin. Again from the specific
activity of the crude material one can calculate the specific activity
per pG or nMole of active heparin species, i. e. of the ACLM
fraction (Table2\.
It should be stressed that these specific activities are inherent
properties of a heparin, defined completely by the catalytic
potencies of the preparation only and independent of the method
with which they are obtained.
Once the specific anti-factor Xa activity of the HAM material
of a given heparin is known, we can use the SIU-Xa level of a
plasma sample to determine its concentration of HAM by simply
dividing that level by the specific anti-factor Xa activity of the
HAM that is administered (16). If our conjecture on the identical
E
d
o
o
o 
,ime after injection 1n1 
10
Fig 2 'Ihe course of ACLM and BCLM levels after injection of UFH
and LMWH. At zero time a subcutaneous injection was given of UFH
(22 rrtg, containing 7 3 mg of ACLM and no detectable BCLM) and of
LMWH (30 mg, containing 3 8 mg ACLM and 3.2 mg BCLM). No
significant levels of BCLM were found when UFH was injected. (From
ref. 16, to which we refer for details on materials and methods)
normal plasma, increases the decay constant of factor Xa by
I min 1 per 1tM of plasmatic AT III.
The heparin activity thus measured is the activity of all HAM,
i. e. both BCLM and ACLM. Varying amounts of ACLM within
the same total amount of HAM will not be distinguished by the
anti-Xa activity. We therefore also need to define a unit of anti-
thrombin activity. The decay velocity of thrombin in plasma
increases proportionally with the ACLM concentration and with
the AT III concentration (17). We can therefore define a
standard- and method independent unit of anti-thrombin activity
completely analogous to the anti-factor Xa unit.
Definition. One standard independent unit of antilhrombin
activity of heparin (SIU-IIa), is that amount of heparin that, in
normal plasma, increases the decay constant of thrombin by
1 min-t per p,M of plasmatic AT IIL
Table 2 Speclfic activities of a LMW heparin and its subfractions
Specific anti-Ila act. per: Spec. anti-Xa act per
Heparin MW
(dalton)
frc
crude
trg
crude
nMole
HAM
nMole
ACLM
nMole
HAM
Fraxiparin
HAM, total
HAM, medium MW
HAM, low MW
HAM, ultralow MW
5,100
5,400
7,740
4,620
3,400
2.36
5.96
16 88
0.62
0.00
>106
79
1,40
7
0
0.72
2.57
1,.7'7
3 .66
3 4 6
17 1.
18 .0
t4 .3
77.8
2 L 0
56
42
t36
3
0
The specific activities are given in min 1 pei unit weight as indicated, determined as described in ref 16 and
with Enoxaparin and Logiparin fractions (B6guin et al. unpublished).
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17. Essentially similar data were obtained
specific activity of all HAM would prove to be true, as suggested
by the data of Thble 2, than the SIU-Xa value would indicate the
number of active HAM molecules in the sample independent of
the type of heparin injected. Also if it is not true, then the SIU-Xa
value still indicates the level of HAM in terms of a mean of the
molar activity. Analogously to the HAM level, the ACLM level
of a plasma sample can be obtained by dividing its SIU-IIa value
by the specific anti-thrombin activity of the ACLM fraction of the
material injected.
Thus the definition of SI units and the determination of specific
heparin activities enables us to assess separately the levels of
ACLM and BCLM (BCLM : HAM - ACLM) in the circulation.
This means that we can discuss heparin pharmacokinetics in terms
of concentrations of active molecules. Pharmacokinetics can in
this way be separated from pharmacodynamics. In order to get an
impression of the heparin concentration of a sample it is no longer
necessary to compare two pharmacodynamic effects such as the
prolongation of the APTT and the thrombotic or bleeding
tendency, Fig.2 gives an example of this approach (from ref. 16).
The TFPI content of the patients sample will as such not
significantly influence the half-life time of thrombin or factor Xa
in plasma. TFPI has no influence on thrombin. The absolute
concentrations of TFPI are maximally 5 nM (20), which is small
compared to the amount of factor Xa used in decay experiments
(around 100 nM). Also the action of TFPI is practically immedi-
ate, so that it will not play a role in the time-domain of a decay
experiment (min). Any other action of TFPI is dependent upon
the presence of tissue thromboplastin, which is absent in anti-
factor Xa assays. TFPI therefore will not significantly influence
the SIU-aXa determination and not at all the SIU-aIIa determina-
tion.
Practical Gonsequences for the Glinical Laboratory:
Anti-Thrombin and Anti-Factor Xa Tests
Any well-designed anti-thrombin test is dependent upon
thrombin breakdown-velocity only. Likewise good anti-factor Xa
activity tests will only measure factor Xa breakdown velocity.
Therefore these tests already measure ft6"., only the results are
not expressed in an appropriate way. If standards calibrated in SI
units would be available, a conversion coefficient can be found for
each method and no important changes in everyday laboratory
practice would be required for the adoption of the SI unit
The results of monospecffic tests can than be expressed directly
in standard independent units by multiplication with the conver-
sion coefficient. This coefficient will be different for different
tests. In any given case it can be determined by calibration of the
test against a k6"" (t',.) determination or against a heparin
preparation of which the potency is known in terms of SI units.
This brings back the heparin standard, but it is no longer the
standard that defines the unit. The standard is now a tool for
calibration that can be abandoned by those who prefer to measure
ka". (t,t) directly. A suitable ACLM preparation can be used to
calibrate both anti-factor Xa tests in terms of SIU-Xa and anti-
thrombin tests in terms of SIU-IIa. In order to see wether the test
under observation is indeed monospecific a BCLM standard can
be used. A monospecific anti-thrombin test will not react to
BCLM at all. A monospecific anti-factor Xa test will give the
same result with an ACLM and a BCLM standard.
Monospecific anti-factor Xa tests can then be used to deter-
mine HAM (in pglml of plasma) and monospecific anti-thrombin
tests can be used to determine ACLM (idem).
Practical Consequences for the Clinical Laboratory:
The Over-All Tests
Reduction of thrombosis or induction of a bleeding tendency is
an over-all effect to which no doubt both ACLM and BCLM
contribute, but to a different extent. Also tests like the APTT in
its many varieties, tests with diluted thromboplastin, the whole
blood clotting time and others, are influenced by both ACLM and
BCLM (see also Table 1). It seems logical to assess the heparin
effect in a patient by an overall test such as the APTT. Underlying
the use of the APTT is the idea that it would be sensitive'to
ACLM and to BCLM in the same way as thrombosis and bleeding
are. This, however, is an unproven assumption In fact there are
substances such as pentasaccharide or dermatan sulfate that
hardly influence the APTT in doses that have a significant
antithrombotic effect (2I,22). This is again seen in Thble 1, from
which it also can be deduced that there is a poor correlation
between the prolongation of the APTT and the inhibition of
thrombin-generation by various kinds of heparin Also the
prolongation of the APTT at a fixed dose of heparin is dependent
upon the individual plasma in which the heparin is dissolved (23).
A fixed prolongation of the APTT can be obtained by a ng/ml
of ACLM or by b nglml of BCLM or by an infinite number of
mixtures of both substances (|ha of ACLM pltts r/zb of BCLM
etc.). A given antithrombotic effect may again be obtained by a
ng/ml of heparin in the patients plasma, but than is not necessarily
also obtained b nglml of BCLM, but e. g. by c ng/ml of BCLM.
There is again an infinite number of mixtures that will have the
same antithrombotic effect, but this series will nol necessarily give
an identical prolongation of the APTT, This shows that the APTT
can be used without problems if we deal with ACLM only (i. e. in
UFH) but looses tether as soon as mixtures with BCLM appear,
i. e. in LMW heparins. The only way to understand what is
indicated by a given prolongation of the APTT is to determine
a ar'd b as in the example above. They will probably differ even
between different types of APTT,
One can imagine an ideal test that reacts to ACLM, BCLM
and all other anticoagulants in the same way as the thrombotic
tendency does. For the moment we can only prove that the
current over-all tests are not suitable candidates It is our guess
that the thrombin potential, i. e. the surface under the thrombin
generation curle might be more suitable for this purpose (24).
Practical Consequences for the Characterisation of Heparins
The approach suggested here would make it possible to
compare directly the amount of anticoagulant material contained
in different preparations of unfractionated as well as low molecu-
lar weight heparin. For this it is required to know: a) the content
of high affinity material (HAM as o/" of total); and b) the
distribution of the high affinity material around the 5,400 dalton
cutoff (ACLM and BCLM as % of HAM). We need also to know:
c) the specific anti-factor Xa activity of the HAM fraction and
d) the specific anti-thrombin activity of the ACLM fraction.
Optionally the specific anti-factor Xa activity of the ACLM and
the BCLM fractions may be given. Again optionally the number
average molecular weight of the HAM and the ACLM fra,ctions,
or preferably the MW distribution, might complete the character-
isation.
With these data (i. e. the heparin dependent constants sub a, b,
c and d), it is possible to express the results of well calibrated
common anti-thrombin and anti-factor Xa activity tests in terms
of circulating concentrations of active (ACLM and BCLM)
heparin.
The biochemical characterisation of the heparin is also a
necessary prerequisite for describing its pharmacological proper-
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ties, were it only because the elimination from the circulation is
significantly different for ACLM and BCLM (16).
Of course we cannot exclude the possibility that non-anticoa-
gulant actions of heparin, notably of its LAM fraction, contribute
to its antithrombotic effects, either by influencing these effects or
by actions that are not related to coagulation. Such actions cannot
be rigorously proven to exist unless exact quantitation of the
anticoagulant effects is possible.
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